Table 1 Clinical characteristics of the entire study cohort
Overall | Discovery cohort | Internal validation cohort | External validation cohort | |||
|---|---|---|---|---|---|---|
CRLM | BD | CRLM | BD | CRLM | ||
n | 405 | 56 | 7 | 154 | 78 | 110 |
Median follow-up time (days) | 1253 | 1302 | 1633 | 831 | ||
Age (median) | 66 | 61 | 60 | 65 | 66.5 | 68 |
Gender (%) | ||||||
Female | 145 (35.8) | 26 (46.4) | 3 (42.9) | 47 (30.5) | 31 (40.0) | 38 (34.5) |
Male | 260 (64.2) | 30 (53.6) | 4 (57.1) | 107 (69.5) | 47 (60.0) | 72 (65.5) |
Residual disease (%) | ||||||
No | 294 (91.9) | 52 (92.9) | 135 (87.7) | 107 (97.3) | ||
Yes | 26 ( 8.1) | 4 (7.1) | 19 (12.3) | 3 (2.7) | ||
Neoadjuvant therapy (%) | ||||||
No | 76 (30.9) | 4 (9.3) | 50 (32.5) | 22 (44.9) | ||
Yes | 170 (69.1) | 39 (90.7) | 104 (67.5) | 27 (55.1) | ||
Tumor differentiation (%) | ||||||
G1-G2 | 129 (83.2) | 17 (73.9) | 19 (63.3) | 93 (91.2) | ||
G3-G4 | 26 (16.8) | 6 (26.1) | 11 (36.7) | 9 (8.8) | ||
TNM (%) | ||||||
IVA | 250 (78.1) | 47 (83.9) | 100 (64.9) | 103 (93.6) | ||
IVB | 70 (21.9) | 9 (16.1) | 54 (35.1) | 7 (6.4) | ||
KRAS (%) | ||||||
Mutant | 64 (41.3) | 12 (30.8) | 52 (44.8) | 0 (0.0) | ||
Wildtype | 91 (58.7) | 27 (69.2) | 64 (55.2) | 0 (0.0) | ||
MSI (%) | ||||||
MSI-L | 9 (8.9) | 4 (36.4) | 5 (21.7) | 0 (0.0) | ||
MSI-H | 92 (91.1) | 7 (63.6) | 18 (78.3) | 67 (100.0) | ||